Objectives
Predictive scores are important tools for triage of COVID-19 patients. The PRIORITY score is advantageous as it does not require laboratory and radiologic information, however the original development and validation cohorts studied only unvaccinated patients in early 2020. We aimed to externally validate the PRIORITY score in a cohort of COVID-19 patients with novel Delta and Omicron variants and mixed vaccination status.
Methods
410 patients were included in a cross-sectional sampling of all patients admitted in the National Centre of Infectious Diseases on 27-October-2021. A further 102 patients and 136 patients with vaccine-breakthrough Delta and Omicron variant infection from April-August and December-2021 respectively were also included. Variables on admission were collected retrospectively from the medical record and used to calculate the probability of deterioration using the PRIORITY model.
Results
Of the total 648 included patients, 447 (69.0%) were vaccinated. Mean age was 61.6 (SD ±19.0) years, and 268 (41.4%) patients were female. 112 (17.3%) met the primary outcome of developing critical illness or mortality. Performance of the score in this cohort was comparable to the original cohorts, with an AUC for all patients of 0.794 (95% CI 0.752–0.835, p<0.001), regression coefficient of 1.069 and intercept of 0.04. Subgroup analysis of unvaccinated and vaccinated patients showed that performance was superior in vaccinated individuals, with AUC of 0.684 (95% CI 0.608–0.760, p<0.0001) and 0.831 (0.772–0.891, p<0.0001) respectively.
Conclusions
Our data support the continued use of the PRIORITY score in this era of novel variants and increased vaccination uptake.